Test predicts if breast cancer chemotherapy will work

June 03, 2002

Reston, Virginia -- Resistance to chemotherapy is a major cause of treatment failure in patients with breast cancer. A study reported in the June issue of The Journal of Nuclear Medicine found that scintigraphic imaging with 99mTc-sestamibi accurately predicted which breast tumors would be chemoresistant.

The study was able to predict 100% of the time which patients would respond to chemotherapy, and 83% of the time which patients would not respond. Physicians in this phase II clinical trial studied 30 patients with untreated locally advanced breast cancer for whom a cycle of chemotherapy followed by surgery was planned. The patients received an injection of 99mTc-sestamibi and were scanned before treatment and again before surgery.

Those who were likely to respond had a low wash-out rate, or WOR (<45%) of the 99mTc-sestamibi. That means a higher amount of it remained in the body after injection, and showed up in the scan. Those unlikely to respond had a higher WOR (>45%). The authors pointed out that knowing a tumor was likely to be chemoresistant would allow physicians to prescribe specific drugs to boost the body's ability to respond to chemotherapy.

Results of the first test were analyzed to determine the amount of radiotracer uptake in the tumor at 10 minutes and 240 minutes, and the washout rate was calculated. The second scan was used diagnostically to confirm tumor response to treatment and the pretherapy therapy result. Results were also confirmed pathologically by the subsequent surgery. Scintigraphy is an imaging technique that uses radioisotopes and a gamma camera.
Prognostic Value of 99MTc-Sestamibi Washout in Predicting Response of Locally Advanced Beast Cancer to Neoadjuvant Chemotherapy was written by Rosa Sciuto, MD, Rosella Pasqualoni, MD, Serenella Bergomi, MD, German Petrilli, MD, Department of Nuclear Medicine, Patrizia Vici, MD, Franca Belli, MD, Second Department of Medical Oncology; Claudio Botti, MD, First Department of Surgical Oncology; Marcella Mottolese PhD, Department of Pathology; and Carlo L. Maini, MD, Department of Nuclear Medicine, all of Regina Elena Cancer Institute, Rome Italy.

Copies of the article and images related to the study are available to media upon request to Karen Lubieniecki at Karenlub@aol.com; (703) 683-0357. Copies of this and past issues of The Journal of Nuclear Medicine are available online at jnm.snmjournals.org. Print copies can be obtained at $15 per copy by contacting the SNM Service Center, Society of Nuclear Medicine, 1850 Samuel Morse Drive, Reston, VA 20190-5315; phone: (703) 326-1186; fax: (703) 708-9015; e-mail: servicecenter@snm.org. A yearly subscription to the journal is $170. A journal subscription is a member benefit of the Society of Nuclear Medicine.

Register online for the June 15-19,2002 SNM Annual Conference www.snm.org

Medical Press Briefing And Image of the Year Monday, June 17, 2002. Press Conference call in: reserve a space contact karenlub@aol.com

Society of Nuclear Medicine

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.